‘Promising’ data on Oxford/AZ, CanSino coronavirus vaccinesData from more than 1,000 healthy volunteers dosed with a coronavirus vaccine developed at Oxford University and AstraZeneca Share X‘Promising’ data on Oxford/AZ, CanSino coronavirus vaccineshttps://pharmaphorum.com/news/first-data-on-oxford-astrazeneca-cansino-coronavirus-vaccines-promising/
Gilead finds survival boost with remdesivir with unorthodox analysisGilead says an analysis of clinical trial and retrospective real-world data suggest remdesivir can improve survival in severe Share XGilead finds survival boost with remdesivir with unorthodox analysishttps://pharmaphorum.com/news/gilead-finds-survival-boost-with-remdesivir-with-unorthodox-analysis/
Trial starts with Imperial College London coronavirus vaccineThe first healthy volunteer has been dosed with Imperial College London’s coronavirus vaccine, the second UK-developed candidate to Share XTrial starts with Imperial College London coronavirus vaccinehttps://pharmaphorum.com/news/trial-starts-with-imperial-college-london-coronavirus-vaccine/
Gilead will test remdesivir in children with COVID-19Gilead Sciences has said it will start trials soon of its antiviral drug remdesivir in children – from Share XGilead will test remdesivir in children with COVID-19https://pharmaphorum.com/news/gilead-will-test-remdesivir-in-children-with-covid-19/
New remdesivir study leaves clinicians guessing about its efficacyThe latest tranche of data with Gilead Sciences’ remdesivir in COVID-19 patients isn’t making it easy to gauge Share XNew remdesivir study leaves clinicians guessing about its efficacyhttps://pharmaphorum.com/news/new-remdesivir-study-leaves-clinicians-guessing-about-its-efficacy/
Atriva takes MEK inhibitor into phase 2 for COVID-19Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, Share XAtriva takes MEK inhibitor into phase 2 for COVID-19https://pharmaphorum.com/news/atriva-takes-mek-inhibitor-into-phase-2-for-covid-19/
Biosig cleared to test merimepodib plus remdesivir in COVID-19US biotech BioSig Technologies’ subsidiary ViralClear has been cleared by the FDA to start a phase 2 trial Share XBiosig cleared to test merimepodib plus remdesivir in COVID-19https://pharmaphorum.com/news/biosig-cleared-to-test-merimepodib-plus-remdesivir-in-covid-19/
Genfit’s NASH hopes are dashed by phase 3 trial failGenfit has seen almost two-thirds of the value wiped off its shares after its much-anticipated pivotal trial of Share XGenfit’s NASH hopes are dashed by phase 3 trial failhttps://pharmaphorum.com/news/genfits-nash-hopes-are-dashed-by-phase-3-trial-fail/
Ferring’s gut microbiome drug clears phase 3 trial in C. diffFerring Pharma has reported what it says is the first positive phase 3 trial of a microbiome therapy Share XFerring’s gut microbiome drug clears phase 3 trial in C. diffhttps://pharmaphorum.com/news/ferrings-gut-microbiome-drug-clears-phase-3-trial-in-c-diff/
